COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,804 Articles (22,527 medRxiv, 8,277 bioRxiv)

Most recent first Previous |  Page 592: Articles 5911-5920  | Next

Does Vaping Increase the Likelihood of SARS-CoV-2 Infection? Paradoxically Yes and No
Phandthong, R., Wong, M., Song, A., Martinez, T., Talbot, P.
10.1101/2022.09.09.507373 — Posted: 2022-09-13
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant
Scheaffer, S. M., Lee, D., Whitener, B., Ying, B., Wu, K., Jani, H., Martin, P., Amato, N. J., Avena, L. E., Berrueta, D. M., Schmidt, S. D., O'Dell, S., Nasir, A., Chuang, G.-Y., Stewart-Jones, G., Koup, R. A., Doria-Rose, N. A., Carfi, A., Elbashir, S. M., Thackray, L. B., Edwards, D. K., Diamond, M. S.
10.1101/2022.09.12.507614 — Posted: 2022-09-13
Monitoring correlates of SARS-CoV-2 infection in cell culture using two-photon microscopy and a novel fluorescent calcium-sensitive dye
Domokos, M., Szalay, G., Cseri, L., Kis, Z., Palyi, B., Foldes, G., Kovacs, N., Fulop, A., Szepesi, A., Hajdrik, P., Csomos, A., Zsembery, A., Kadar, K., Katona, G., Mucsi, Z., Rozsa, B. J., Kovacs, E.
10.1101/2022.09.12.506773 — Posted: 2022-09-13
Comparative multi-OMICS single-cell atlas of five COVID-19 (rAdVV and mRNA) vaccines describe unique and distinct mechanisms of action
Singh, Y., Schulze-Selting, A., Gabernet, G., Ray, U., Bajaj, R., Ali, M., Loitz, M., Hammer, V., Buena-Atienza, E., Ruschil, C., Huebner, J., Kowarik, M., salker, M., Casadei, N., Nahnsen, S., Kremsner, P., Ossowski, S., Altmann, D. M., Deutsche COVID-19 OMICS Initiative (DeCOI), , Riess, O.
10.1101/2022.09.12.507666 — Posted: 2022-09-13
Humoral immunogenicity of a Coronavirus Disease 2019 (COVID-19) DNA Vaccine in Rhesus Macaques (Macaca mulatta) Delivered using Needle-free Jet Injection
Jay, A., Kwilas, S. A., Josleyn, M., Ricks, K., Hooper, J. W.
10.1101/2022.09.12.507647 — Posted: 2022-09-13
Evaluation of endogenous and therapeutic 25-hydroxycholesterols in murine models of pulmonary SARS-CoV-2 infection
Fessler, M. B., Madenspacher, J., Baker, P. J., Hilligan, K. L., Castro, E., Meacham, J., Chen, S.-H., Johnson, R. F., Martin, N. P., Tucker, C. J., Mahapatra, D., Cesta, M., Mayer-Barber, K. D.
10.1101/2022.09.12.507671 — Posted: 2022-09-13
A general theory for infectious disease dynamics.
Carbone, G., De Vincenzo, I.
10.1101/2022.09.12.22278744 — Posted: 2022-09-13
The SARS-CoV-2 Spike Protein Mutation Explorer: Using an Interactive Application to Improve the Public Understanding of SARS-CoV-2 Variants of Concern
Iannucci, S., Harvey, W. T., Hughes, J., Robertson, D. L., Poyade, M., Hutchinson, E.
10.1101/2022.09.09.507349 — Posted: 2022-09-12
Determinants restricting ACE2 recognition of MERS-related coronaviruses in bats
Ma, C., Xiong, Q., Gu, M., Wang, C., Shi, L., Liu, C., Si, J., Tong, F., Liu, P., Huang, M., Yan, H.
10.1101/2022.09.11.507506 — Posted: 2022-09-12
Clomipramine inhibits dynamin L-α-phosphatidyl-L-serine stimulated GTPase activity
Miyoshi, H., Otomo, M., Takahashi, K.
10.1101/2022.09.09.507370 — Posted: 2022-09-12

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).